Corteva, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTVA research report →
Range $11 – $101
Price Chart
About the company
Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection.
- CEO
- Luke C. Kissam
- IPO
- 2019
- Employees
- 21,500
- HQ
- Indianapolis, IN, US
AI snapshot
Six angles, distilled from the data.
CTVA remains in a damaged multi-month downtrend, trading well below its 200-day moving average after a sharp reset from the 52-week high. The stock is still closer to the yearly low than the prior peak, so the regime favors repair rather than momentum until it reclaims longer-term trend levels.
Street sentiment is still constructive, with a Buy consensus and an average target of 30.73, but the target stack has been cut hard in recent weeks. RBC lowered its target to $11 and Oppenheimer downgraded to Perform, while several firms still sit in the mid-teens to high-teens range, signaling caution after the reset.
The earnings profile is mixed: Corteva has beaten in 6 of the last 8 quarters, but the latest print missed badly at -$0.04 versus $0.09 expected. Next-year EPS estimates sit at 1.124, below the current TTM 1.3, so shareholders should watch whether margin pressure and guidance stabilize.
No discretionary insider buying or selling stands out. The recent filings are dominated by director award grants and zero-share officer entries, which read as routine compensation activity rather than a conviction signal.
Profitability is solid but not elite, with a 33.2% gross margin, 10.51% operating margin, and 2.76% net margin. Growth has softened, with revenue down 1.2% year over year and earnings down 9.9%, but the balance sheet is strong with $1.95 billion in net cash.
Corteva screens as a cash-generative agricultural inputs name with better balance-sheet flexibility than many peers, but the market is discounting slower growth and lower earnings power. At 2.56x earnings, the valuation is depressed versus the broader sector and reflects the post-reset skepticism.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.27B
- P/E
- 6.71
- Fwd P/E
- 11.59
- PEG
- -0.14
- P/S
- 0.31
- P/B
- 0.22
- EV/EBITDA
- 2.92
- Div Yield
- 1.33%
- Gross Margin
- 48.61%
- Op Margin
- 16.04%
- Net Margin
- 4.30%
- ROE
- 3.09%
- ROIC
- 5.13%
Latest fiscal year · YoY change
- Revenue
- $17.40B+2.9%
- Gross Profit
- $8.23B+11.5%
- Op Income
- $2.62B
- Net Income
- $1.09B+20.6%
- EPS
- $1.60+22.1%
- OCF Growth
- +58.8%
- FCF Growth
- +81.8%
- 52W High
- $14.62
- 52W Low
- $7.82
- 50D MA
- $11.95
- 200D MA
- $12.08
- Beta
- 0.59
- RSI (14)
- 22
- Avg Volume
- 31.88M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Corteva posted mixed Q3 2026 results: growth and execution were solid outside Brazil, but severe channel inventory and pricing pressure in Brazil forced the company to cut full-year EBITDA guidance.· November 12, 2026
- Q3 net sales were $1.6 billion, down 9% year over year, while operating EBITDA was $222 million, down 17%, and margin was 14%, down 140 bps.
- Year to date, net sales were $5.4 billion, down 1%; organic sales were down 4%; operating EBITDA was $943 million, essentially flat, with margin up 30 bps despite about $230 million of pricing headwinds.
- North America, EMEA, and Asia Pacific all grew in the quarter, helped by new products and productivity, while Latin America sales fell sharply as Brazil deteriorated.
- The company cut full-year 2026 operating EBITDA guidance to $1.1 billion-$1.125 billion from about $1.3 billion, and now expects operating EPS of $0.76-$0.80.
- Management said Brazil inventory normalization is the main issue, while the board declared the first quarterly dividend as a stand-alone company and the company remains on track for about $1.5 billion of cash at year-end.
Third-quarter 2026 net sales were $1.6 billion, down 9% versus prior year on both reported and organic basis. Operating EBITDA was $222 million, down 17%, and operating EBITDA margin was 14%, down 140 basis points. Year to date, net sales were $5.4 billion, down 1%, organic sales were down 4%, operating EBITDA was $943 million, essentially flat, and margin expanded 30 basis points despite more than approximately $230 million of pricing headwinds. Regionally, North America sales were up 7% with volume up 19%, EMEA grew 12% (14% organic), Asia Pacific grew 3% (5% organic), and Latin America sales were down about $220 million with volume down 24% and price down 7%. Full-year 2026 operating EBITDA guidance was reduced to $1.1 billion-$1.125 billion from about $1.3 billion, implying about 12% down year over year at the midpoint and a margin of about 15%. Full-year operating EPS is expected to be $0.76-$0.80 per share, up about 3% at the midpoint. Management said the Q4 EBITDA is now expected to be about half of 2025 levels on an adjusted pro forma basis.
Luke Kissam framed the quarter as proof that Corteva’s innovation-and-execution strategy is working outside Brazil, pointing to 20% growth in new product volumes and growth in every region except Latin America. He repeatedly said Brazil is the outlier and top priority, citing weak grower economics, high rates, weather, and elevated channel inventory, and he said the team is reviewing structure, costs, and even market approach in Brazil. His tone was candid and constructive: encouraged by the broader business, but direct that Brazil requires action and that cost and complexity must come out of the company.
Jeff Rudolph focused on the financial bridge: Q3 price was the main headwind, with about $120 million of pressure in the quarter, roughly 90% from U.S. acetochlor and Brazil generics, while productivity and lower SG&A more than offset higher R&D for a net $67 million benefit on costs. He said the full-year EBITDA reduction is driven by Brazil, including about $100 million tied to elevated channel inventory, and that the company is not assuming meaningful improvement in Brazilian buying behavior for the rest of the year. On cash, he said Corteva ended Q3 with about $1.8 billion of cash, still expects roughly $1.5 billion by year-end, and sees 2027 cash conversion roughly in line with Investor Day expectations, with CapEx around a $200 million annual run rate and buybacks part of 2027 deployment priorities.
Analysts pressed management on whether to separate the business into Brazil versus everywhere else, whether acetochlor price pressure would persist into 2027, whether the issue was destocking or lower on-farm demand, and whether Brazil remains worth competing in long term. Management said the Brazil problem is mainly channel inventory plus weaker market conditions, that on-farm share appears intact, and that the full-year guide cut is 100% Brazil-driven. On acetochlor, Luke and Jeff said the price impact continues in Q4 and into early 2027 but should taper materially by the second quarter of 2027, while management said Brazil inventory should be back to more acceptable levels by the end of the growing season.
Outside Brazil, Corteva said its strategy is working: new product volumes rose 20%, and North America, EMEA, and Asia Pacific all posted organic growth despite a tough operating backdrop. Management was also encouraged by productivity gains, tighter SG&A, and a strong pipeline, and it expects to reach a more normalized Brazil inventory position by the end of the growing season. Luke also said the company expects to grow in 2027 and sees buybacks as an attractive use of cash.
Brazil remains the clear risk, with Latin America sales down 31% in the quarter and management saying conditions worsened late in Q3 and have continued to deteriorate. The company expects the Brazil overhang to weigh on Q4 and has lowered full-year EBITDA by roughly $175 million to $200 million versus prior expectations. Pricing pressure is also still active in U.S. acetochlor and in Brazil generics, and management acknowledged that the company may need a broader transformation to lower cost and complexity.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 667.32M
- Float Shares
- 666.90M
of shares held by institutions
1,530 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CTVA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Oct 14, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 17, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Oct 29, 24 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Gary C. PetersSenate · MI | Sell | Apr 23, 26 | Filing → |
| Markwayne MullinSenate · OK | Sell | Jan 4, 24 | Filing → |
| Markwayne MullinSenate · OK | Sell | Dec 22, 23 | Filing → |
| Markwayne MullinSenate · OK | Buy | Jan 3, 23 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Oct 29, 24 | Filing → |
| John JamesHouse · MI10 | Sell | Sep 4, 24 | Filing → |
| John JamesHouse · MI10 | Buy | Nov 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 13, 24 | Filing → |
| Markwayne MullinSenate · OK | Sell | Dec 22, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 80.54M | ▲ 317.54K |
| Fmr LLC | 55.69M | ▲ 14.61M |
| Blackrock, Inc. | 52.79M | ▼ 1.06M |
| Capital World Investors | 49.46M | ▲ 6.54M |
| Vanguard Capital Management LLC | 43.67M | ▼ 124.43K |
| State Street Corp | 37.54M | ▼ 721.44K |
| Vanguard Portfolio Management LLC | 29.53M | ▼ 268.89K |
| Geode Capital Management, LLC | 20.07M | ▲ 1.17M |
| Aristotle Capital Management, LLC | 16.56M | ▼ 1.21M |
| Harris Associates L P | 12.32M | ▼ 4.01M |
| Northern Trust Corp | 11.35M | ▼ 716.72K |
| Wcm Investment Management, LLC | 9.35M | ▲ 409.85K |
Held by 1,185 ETFs
Biggest fund positions in CTVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | PAGE GREGORY R | buy | 10,000 |
| Nov 13, 26 | PAGE GREGORY R | buy | 10,000 |
| Nov 13, 26 | KISSAM LUTHER C IV | buy | 32,292 |
| Oct 30, 26 | Policinski Christopher J. | other | 2,792.096 |
| Oct 30, 26 | Nayyar Nayaki R | other | 2,792.096 |
| Oct 30, 26 | Giesselman Janet Plaut | other | 665.808 |
| Oct 1, 26 | Sloan Jennifer L. | other | 0 |
| Oct 1, 26 | Sloan Jennifer L. | other | 0 |
| Oct 1, 26 | Sloan Jennifer L. | other | 0 |
| Oct 1, 26 | Sloan Jennifer L. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTVA coverage
Recent articles, reports, and earnings notes.

Corteva (CTVA): Earnings Recovery Meets Separation Risk
Corteva’s earnings are improving, with 1H 2026 sales, EBITDA, and EPS all rising, but valuation and the planned 2026 separation keep the setup balanced. The stock looks attractive for moderate-risk investors if execution stays on track.

Corteva, Inc. (CTVA) crashes after Vylor spin-off
Corteva, Inc. (CTVA) crashes in after-hours trading after its October 1 separation of the seed business into Vylor. The move appears tied to the corporate action, not a fresh earnings miss, and investors should evaluate the combined value of CTVA and Vylor before drawing conclusions.

Inside Our Top Fertilizer and Crop Inputs Stock Picks for November 2026
A seven-stock countdown spans lawn care, crop protection, nitrogen, potash and phosphate, with Scotts, FMC, Corteva, Intrepid Potash and CVR Partners among the named companies.
Want a deeper read on CTVA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
2 Farm ETFs Own What Every Grocery Store Depends On
247wallst.com · Nov 20
Corteva: Brazil Issues Will Eventually Ease
seekingalpha.com · Nov 19
CTVA Investors Have Opportunity to Join Corteva, Inc. Fraud Investigation with SBS Law
gurufocus.com · Nov 18
CTVA Investors Have Opportunity to Join Corteva, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 18
Did You Lose Money on Corteva, Inc. Stock? The Law Offices of Howard G.
businesswire.com · Nov 16
432,151 Corteva, Inc. $CTVA Shares Bought by Aberdeen Group plc
defenseworld.net · Nov 15
Lost Money on Corteva, Inc. Shares? The Law Offices of Frank R.
businesswire.com · Nov 13
Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut
zacks.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice